Physician

Bobbie Head, M.D., PHD

According to 2025 Medicare claims, Bobbie Head, M.D., PHD (NPI: 1053412403) practices medical oncology in the San Rafael, CA market, with the plurality of this provider's patient population coming from Marin, CA. This provider's primary affiliated billing organization is MARIN CANCER CARE, INC. (NPI: 1629370499; TIN: 272191391) and primary practice location at 94904-2018.

Head's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 416 traditional Medicare patients, billed 74,136 HCPCS/CPT codes, and received $1,377,710 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,385 prescription claims across 293 beneficiaries totaling $2,210,161 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 98 claims. Open Payments data shows 2 records totaling $133,267. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,285,844 and ending at $1,377,710. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $365,462 to $2,210,161. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $3,758 to $919.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	404	98,414	$1,285,844
2016	463	115,777	$1,505,172
2017	410	90,023	$1,563,303
2018	362	84,585	$1,504,931
2019	386	71,344	$1,089,429
2020	408	108,446	$1,775,830
2021	458	114,131	$2,264,656
2022	409	123,062	$2,322,940
2023	403	97,557	$1,833,145
2024	416	74,136	$1,377,710

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	192	1,272	$365,462
2016	212	1,569	$463,900
2017	243	1,694	$412,559
2018	241	1,619	$973,282
2019	246	1,553	$1,343,493
2020	250	1,552	$1,240,110
2021	276	1,625	$1,623,617
2022	278	1,497	$2,100,365
2023	274	1,340	$1,448,951
2024	293	1,385	$2,210,161

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	133	$44,315
2016	N/R	62	$24,343
2017	N/R	70	$17,357
2018	N/R	N/R	N/R
2019	N/R	91	$6,910
2020	N/R	96	$6,775
2021	12	106	$6,977
2022	N/R	59	$2,788
2023	N/R	89	$17,084
2024	12	98	$2,063

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	49	49	$184
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	327	652	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	71	96	$73
96372	Injection of drug or substance under skin or into muscle	50	111	$12
J7030	Infusion, normal saline solution , 1000 cc	39	371	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	38	1,134	$591,575
Verzenio	Abemaciclib	27	756	$450,781
Kisqali	Ribociclib Succinate	21	588	$211,289
Ibrance	Palbociclib	13	376	$182,445
Lenalidomide	Lenalidomide	12	336	$83,775

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	41	$1,166
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	12	29	$546
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	28	$351

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$35	Medtronic, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$133,231	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bobbie Head, M.D., PHD?

Tedicare shows public-source Medicare data for Bobbie Head, M.D., PHD (NPI 1053412403), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bobbie Head, M.D., PHD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Bobbie Head, M.D., PHD?

Bobbie Head, M.D., PHD is linked to MARIN CANCER CARE, INC. (billing NPI 1629370499) in the available physician profile data.

Does Bobbie Head, M.D., PHD have Open Payments data?

Bobbie Head, M.D., PHD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.